Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

UNOS applauds introduction of the Organ Donation Referral Improvement Act

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) today applauded the introduction of the bipartisan Organ Donation Referral Improvement Act by U.S. Reps. Rob Wittman, Jennifer McClellan, Mariannette Miller-Meeks and Jim Costa. The bipartisan legislation aims to optimize the deceased organ donor referral process by identifying and recommending best practices for software tools used by hospitals and organ procurement organizations. This will help to maximize potential organ donation while reducing the burden on busy hospital staff and will ultimately improve patient access to transplants. “We are pleased to see this important legislation introduced,” said Maureen McBride, Ph.D. CEO of UNOS. “By leveraging technology, we can streamline the organ donor referral process to increase organs available for transplant and save more lives. UNOS is committed to working with Congress and the entire organ donation and transplant community to advance the Organ Donation Referral Improvement Act and ensure a safe and efficient organ donation and transplant system for all. Thank you, Representatives Wittman, McClellan, Miller-Meeks and Costa for your leadership on this critical issue.” UNOS calls upon the U.S. House Committee on Energy and Commerce to quickly take up this important legislation. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Company Website https://unos.org

October 04, 2024 02:00 PM Eastern Daylight Time

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Benzinga

By Josh Enomoto, Benzinga Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a lancet to prick their fingers and apply a drop of blood to a test strip – represented the norm. Still, even with the rise of CGM, several challenges remain. That’s what Glucotrack Inc. (NASDAQ: GCTK) is looking to address. In particular, while current CGM solutions have improved quality of life via informed decision-making, several obstacles – including discomfort and inconvenience – have left many patients as well as medical professionals wanting. Glucotrack aims to fill the opportunity gaps in the CGM industry by directly addressing the pain points of the contemporary standard of care. Most importantly, Glucotrack’s mainline innovation – known as the Continuous Blood Glucose Monitor (CBGM) – focuses on the patient. Diabetes affects 38 million people in the U.S. alone, according to the CDC, and it's the eighth leading cause of death, contributing to serious complications like kidney disease, blindness and cardiovascular risk. With such a vast population facing the daily burden of managing their blood sugar, innovations like Glucotrack’s real-time monitoring system could be essential to improving quality of life and healthcare outcomes. Assessing The Current State Of CGM Technology According to a publication posted by the National Library of Medicine, the U.S. Food and Drug Administration (FDA) approved the first “professional” CGM in 1999. Since that time, there have been several major advancements in the technology. However, commercially available CGMs tend to measure glucose in interstitial fluid and not directly from blood. And, until relatively recently, all CGM devices required calibration via blood glucose measurements extracted from the fingerstick process. Generally, the calibration process is used to improve system accuracy by comparing it to a blood glucose measurement from a fingerstick. Even with the latest advancements, several challenges and inconveniences remain. Among the most vexing for patients is a lack of a platform that addresses all major concerns. Instead, sufferers of diabetes must compromise across a range of different sets of pros and cons. Abbott Laboratories (NYSE: ABT) has established a strong presence in diabetes management with its CGM system, FreeStyle Libre. Libre offers accurate and continuous glucose monitoring, but the platform also requires frequent sensor changes (every 14-15 days, depending on the model) and the use of a wearable. Dexcom (NASDAQ: DXCM) is also among the leaders in CGM technology, offering accurate and continuous glucose tracking. However, reports indicate the company’s platform falls short in terms of the adhesive patch potentially not properly sticking to the patient’s skin at all times. Senseonics Holdings Inc. (AMEX: SENS) has gained in popularity thanks to its product Eversense, an implantable CGM with a sensor life of up to six months, with the FDA recently clearing use for one year. While an enticing proposition, the system requires frequent calibration and patients still need to wear a transmitter over the skin. Medtronic PLC (NYSE: MDT) represents another of the innovative powerhouses in diabetes care, with its CGM integrated into a broader diabetes management ecosystem. Nevertheless, the underlying platform still requires regular calibration and the use of wearables. In contrast, Glucotrack seeks to address these shortcomings of contemporary CGM devices. One of the most distinct advantages of the company’s solution is a much longer sensor life. Moreover, it does away with wearables while providing real-time blood glucose monitoring. Key Advantages Of The Glucotrack System As mentioned earlier, sensor life represents a core struggle of many diabetes patients managing their condition. On one end of the scale, Abbott’s FreeStyle Libre, Dexcom systems and Medtronic systems offer a relatively pain-free sensor application process. However, the sensor requires replacement after 7-15 days, depending on the model. On the other hand, Senseonic offers a sensor life of up to half a year, with one-year recently approved by the FDA. This system is implantable, but still requires the need for a wearable transmitter, which impacts the patient’s quality of life. Furthermore, according to internal market research performed by Glucotrack, 73% of endocrinologists favor devices with a sensor life of three years. As shared in an earlier Benzinga article, the key advantage of the Glucotrack system is that the underlying implantable CBGM features a sensor that can last up to three years. That’s a significant improvement over many more popular options, thus reducing the frequency and hassle of updating prescriptions and ordering supplies. Speaking of organic benefits, Glucotrack’s device eliminates the need for wearables. This advantage automatically resolves common concerns tied to continuous glucose monitoring, including adhesive skin irritation, sensor detachment during activities and the burden of managing supplies and copayments. Another important attribute of the Glucotrack system is its real-time blood glucose measurement capabilities. Such measurements may provide much more accurate readings because the use of blood dramatically cuts the lag time present in traditional interstitial glucose monitors. Significantly, real-time measurements may potentially facilitate improved safety. Thanks to the quicker testing data, patients may be able to respond more quickly to urgent matters, such as low or high blood sugar events. This attribute may potentially reduce the risk of severe complications like diabetic ketoacidosis or hypoglycemic coma. A core advantage that Glucotrack claims is CBGM’s broad interest among healthcare professionals. The company recently conducted proof of concept research among 100 endocrinologists and 50 primary care providers (PCPs), which yielded much data, including the following statistics: Finding the implantable CBGM concept an intriguing and innovative one, 42% of endocrinologists expressed willingness to adopt the platform following approval and at a sensor life of only two years. Even more so than endocrinologists, PCPs have vocally expressed eagerness to try the implantable CBGM, with 68% willing to adopt the system at a sensor life of only two years. Individual PCPs reported that Glucotrack’s device can be a “game changer for diabetics,” along with labeling the concept itself as “genius.” Finally, Glucotrack offers an intuitive interface, requiring minimal calibration and thus reducing the daily burdens that patients must follow. Rising Need For CGM Innovation According to Lancet’s global burden studies, chronic conditions represented the root of 74% of all deaths across the world. That’s a noticeable rise from 67% of deaths in 2010, reflecting the rising prevalence of chronic diseases, of which diabetes is one. As such, the rise of diabetes – particularly type 2 and prediabetes – represents a significant area of concern. However, for Glucotrack, the main focus is on insulin-using people with diabetes, as these patients require continuous monitoring due to insulin therapy. With this population segment also growing, finding advanced solutions to address their unique challenges becomes even more critical. It’s not just about the inconveniences of frequent sensor changes and the irritation and discomfort involved in everyday utilization of standard CGM devices. It’s often also limiting the ability to participate in some activities such as swimming or hot yoga due to concerns about the wearable falling off. By facilitating a long-lasting alternative, Glucotrack’s CBGM makes glucose monitoring less intrusive and potentially more accessible. Most significantly, the accuracy behind real-time glucose measurements reported by the company may potentially improve quality of life and in some acute situations save it. Empowering Diabetes Care With Real-Time Solutions In an ever-growing diabetes landscape, Glucotrack’s advancements in continuous glucose monitoring offer a potential solution to the persistent challenges faced by insulin-using people with diabetes. By addressing key pain points such as short sensor life, the discomfort of wearables and the hassle of frequent replacements, Glucotrack potentially positions itself as a transformative force in diabetes care. Additionally, with its reported real-time, accurate blood glucose measurements, long-lasting sensor and lack of an intrusive wearable, the CBGM system not only improves day-to-day management but also has the potential to prevent life-threatening complications. As the need for better diabetes care intensifies, Glucotrack is looking to offer a brighter, healthier future for millions of people managing this chronic disease. Featured photo by Brooke Cagle on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 04, 2024 08:30 AM Eastern Daylight Time

Image

Holiday Gift Guide: Add These Luxury Cannabis Items to Your Shopping List

MJ Attaché

Cannabis is legal in 38 states and counting for medical use. Almost 40% of women over the age of 21 currently consume cannabis, and men are nearly twice as likely to use cannabis than women. Odds are, your holiday gift-giving list includes an herbalist who would cherish an easy and elegant addition to their self-care ritual. “Whether the cannabis connoisseur on your holiday giving list uses cannabis medicinally or recreationally, MJ Attaché gift options elevate the experience and simplify the lives of discerning herbal enthusiasts,” explains MJ Attaché founder Christy Fuicelli. “Not only are our attachés statement pieces for self-care rituals, but they’re discreet, lockable and customizable to suit individual consumption needs.” New-to-market, MJ Attaché luxury holiday gift options for cannabis enthusiasts The Anthony Bag - $2,150.00 The Anthony bag combines style and sophistication for the discerning herbalist. Built by Italian artisans with the finest materials, this attaché dispels outdated stereotypes and elevates self-care rituals with patent-pending technology. It is the first on the market to provide a subtle, smell-disguising, practical and elegant solution to suit a cannabis enthusiast’s lifestyle. Available in five colors, The Anthony contains a removable rolling tray and magnetic accessories for customizable storage of your cannabis and accouterments. Retractable Vape Pen Holder - $150.00 Give the gift of ease, and the herbalist on your list will never lose another vape pen. Made in Italy of metal, leather and elastic, this accessory ensures the safekeeping and easy access of a favorite pen. The branded snap hook clips to bags or clothing, and the monogrammed retractable piece allows for use without removal. Fits most batteries up to.5″ in diameter. Retractable Lighter Holder - $175.00 Place this holder under the tree, and your favorite cannabis enthusiast’s lighter will always be at hand. Like the pen holder, this lighter holder is made in Italy of metal and leather. It is engineered to ensure a lighter’s safekeeping and easy access. The accessory’s branded snap hook clips to clothing or bags for accessibility, and the monogrammed retractable piece allows for use without removal. Fits classic BIC lighter. “Our vape pen and lighter holders keep your cannabis accessories safe and right where you need them. The Anthony is a luxury storage solution for all your cannabis needs—making it the perfect gift for a sophisticated herbal enthusiast,” says Fuicelli. “In addition to beauty and refinement, The Anthony is equally functional in that the components can be customized to meet individual needs. For example, edibles, flower and prerolls can be stored in the provided smell-proof jars and locked in The Anthony bag for safekeeping and transport this holiday season,” Fuicelli explains. The Anthony bag makes cannabis self-care rituals easy and elegant Discreet, smell-disguising design you can take anywhere Patent-pending modular elements include smell-proof jars for edibles and flower, lighter holder and glass holder Removable rolling tray for ease of use and clean-up Zipper lock eliminates need for difficult-to-open childproof containers "The Anthony bag not only keeps all my sesh products nicely organized for on-the-go, but it also turns heads. All my colleagues are shocked to find out its purpose!" says Arend Richard, The Anthony bag purchaser and founder of Cirrus Social Club in Denver. Find holiday luxury at MJAttache.com. Connect on Facebook and Instagram for the latest updates and deals. # # # About MJ Attaché Launched in April 2024, MJ Attaché is a designer and developer of high-quality, handmade Italian leather bags and accessories for the cannabis connoisseur. The luxury brand, with its moniker “MJ” (short for Mary Jane—an alias for marijuana), was founded by entrepreneur Christy Fuicelli, a stylish herbalist. Realizing a void in the marketplace, Fuicelli created MJ Attaché to cache and carry her cannabis in a discreet manner reflective of the luxury she enjoyed in other personal products. Fuicelli spent years designing beautifully crafted bags that embody elevated style, sophistication, high quality and fine craftsmanship. Appealing to men and women alike, MJ Attaché products bring ease and style to the cannabis industry and challenge outdated stigmas. Contact Details MJ Attaché Katie Converse for MJ Attaché info@mjattache.com Company Website https://mjattache.com/

October 03, 2024 01:00 PM Mountain Daylight Time

Image

This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Pancreatic cancer is one of the most aggressive and painful forms of cancer, often leaving patients with limited options for effective pain management. Traditional treatments like opioids and nerve blocks offer only temporary relief, and their side effects can further diminish the quality of life. This underscores the urgent need for innovative solutions that can provide sustainable pain relief for those battling this debilitating disease. Autonomix Medical (NASDAQ: AMIX) is working to address this critical gap with a novel, non-opioid approach designed to significantly reduce pain in pancreatic cancer patients. The company recently shared promising preliminary data from its ongoing human clinical trial, showcasing the potential of its precision nerve-targeted treatment. This minimally invasive method aims to deliver lasting pain relief, offering hope to patients who have struggled to find effective alternatives to around-the-clock opioids. “We are encouraged by the significant, sustained pain reduction demonstrated from the lead-in patients in our ongoing first-in-human trial. These are very sick individuals, who up until this point primarily relied on opioids to help mitigate their pain, which our baseline data shows were not effective,” said Autonomix CEO Brad Hauser. Overview Of Preliminary Results In early September, Autonomix announced positive outcomes from its proof-of-concept trial. The results indicated that 60% of patients in the initial cohort experienced a substantial reduction in pain. Using the Visual Analog Scale (VAS), patients reported a dramatic drop in pain scores from an average of 8.0 to just 1.33 within 4 to 6 weeks post-procedure — an 83% reduction. Significantly, patients in the responder group felt pain relief as early as one day after the procedure, highlighting the potential for rapid and meaningful impact. The trial also identified a key factor that may factor in treatment success: the access point used during the procedure. Patients treated through femoral access showed significant improvements, while those with brachial access did not. These findings suggest that the method of delivery may play a crucial role in optimizing outcomes. Innovative Technology Behind The Treatment Autonomix reports that its groundbreaking technology employs a catheter-based microchip sensing array capable of detecting and differentiating nerve signals with extraordinary precision – up to 3,000 times greater than existing methods. The company says this advanced platform not only identifies overactive nerve signals but also targets them with radiofrequency (RF) ablation, providing precise pain relief without the common drawbacks of conventional treatments. Looking Ahead: Expanding The Possibilities The trial is expected to complete patient enrollment by the end of 2024, with plans to incorporate additional biomarkers to refine the correlation between nerve ablation and pain relief. The success of this trial could pave the way for a new standard in pain management, extending beyond pancreatic cancer to other conditions characterized by severe nerve-related pain. A Potential Game-Changer, Non-Opioid Approach In Pain Therapy Autonomix Medical could be poised to help revolutionize pain management, not only for pancreatic cancer patients but for a broader range of chronic pain conditions. As their technology evolves and clinical trials progress, the company says its approach could transform the landscape of pain therapy, offering hope and improved quality of life to countless individuals. By developing cutting-edge solutions, Autonomix is not just addressing a critical unmet need but also potentially setting the stage for a new era in precision pain management. With the potential to impact a significant segment of the multi-billion-dollar pain management market, this breakthrough could mark a turning point in the way we treat pain in complex medical conditions. Featured photo by Ousa Chea from Unsplash. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

October 03, 2024 08:35 AM Eastern Daylight Time

Image

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Forum Health Launches Revolutionary PNOĒ Metabolic Device Transforming Weight Management, Fitness and Longevity

Forum Health

Forum Health, a premier provider of personalized integrative and functional medicine, announces the launch of the PNOĒ metabolic analysis device, offering precise insights into metabolic, heart, lung, and cellular health for personalized wellness. Now available in Forum Health’s Madison and Fond du Lac, Wisconsin clinics, the PNOĒ uses a data-driven approach to weight management, fitness, and longevity optimization. Schedule a PNOĒ assessment here: Fond du Lac or Madison. Julie Heyrman, MD: "We’re thrilled to bring this advanced technology to our patients in Wisconsin. The PNOĒ allows us to better tailor health solutions that address the root causes of weight gain, fatigue, aging, and cardiovascular risk." Through using only breath, the PNOĒ provides a comprehensive metabolic analysis on how effectively the body burns calories, the efficiency of the heart and lungs, and overall cellular performance. Patients receive personalized health plans tailored to their unique metabolic profile for improved wellness and disease prevention. Key Benefits of PNOĒ Metabolic Analysis: Precision Weight Management: Analyzes metabolism to optimize workouts, calorie intake, and macronutrient balance for sustainable weight management. Endurance Enhancement: Measures the efficiency of heart, lungs, and cells, identifying limiting factors and providing a customized plan to overcome them. Longevity Optimization: Calculates VO2 max, cellular health, and metabolic efficiency—key predictors of lifespan and well-being. Early Detection - Detects early risk factors for heart, lung, and metabolic conditions, empowering proactive health steps. Phil Hagerman, CEO: “Forum Health is committed to bringing the most advanced technologies to our patients, and the PNOĒ device represents a new frontier in personalized healthcare. By offering precise metabolic insights, we can create tailored health plans that drive better outcomes for the health issues most affecting our patient's overall well-being.” About PNOĒ PNOĒ is a state-of-the-art metabolic analysis device that provides comprehensive assessments of heart, lung, and cellular fitness through breath analysis. Learn more at pnoe.com. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

October 01, 2024 08:50 AM Eastern Daylight Time

Independent Living And Safety: How LogicMark's Innovations Are Helping To Address The Needs Of An Aging America

Benzinga

By Gerelyn Terzo, Benzinga Check out LogicMark’s investment deck here. In America, more than 10,000 Baby Boomers reach the milestone age of 65 each day. By 2040, 25% of the American population will be over the age of 65. Meanwhile, senior citizens are choosing to live life independently more than ever before, a shift that has gained momentum in the wake of the pandemic. These days, nearly three-quarters (70%) of Americans shudder at the thought of being admitted into a nursing home, a Gallup poll revealed. Additionally, almost two-thirds of families would hesitate to admit a loved one to a nursing home facility. However, living independently introduces a host of other challenges that must be overcome. While emergency and safety needs have evolved over the past several decades, personal safety solutions often lag behind and don’t keep pace with modern technological standards. This has an impact on vulnerable communities, as well as the “sandwich generation” – many of whom are caring both for their own children as well as their aging parents. Why Seniors Are Vulnerable To Falling In reality, the leading cause of injury and death for senior citizens over the age of 65 is falling, and with more of the aging population living independently, the trend is only getting worse, according to the U.S. Centers for Disease Control and Prevention (CDC). In fact, of the roughly 58 million Americans age 65 or older, one in four report experiencing a fall, based on historical data from the CDC, a growing problem they admit can be prevented. Dr. Esiquio Casillas, Senior Vice President and Chief Medical Officer for the AltaMed Health Services Program of All-Inclusive Care for the Elderly, explained the cause, saying, “That’s because aging affects our muscle strength and flexibility, making it more challenging to maintain balance and stability. Older adults are also more likely to have chronic conditions that can affect their mobility, coordination and overall stability. Plus, age-related vision changes and hearing loss can make it harder to navigate and identify potential hazards.” Recognizing these concerns, LogicMark (NASDAQ: LGMK), with nearly two decades in the personal safety products market, has developed an entire suite of solutions, including personal emergency response systems (PERS), health communications devices and internet-of-things (IoT) technologies for a connected care platform. LogicMark says its technology harnesses data to identify risks while anticipating needs and protecting data privacy. It carries the potential to reverse a troubling and dangerous trend of death from accidental falls. Considering the growth that the senior medical alerts/PERS market is set to experience, with the market opportunity projected to reach $17.26 billion by 2028 – reflecting a compound annual growth rate of 10.6% – LogicMark could be strategically positioned to capitalize on this trend. LogicMark’s Business Evolution Since its founding in 2006, LogicMark has become a leader in personal safety. Early in its inception, the company relied heavily on reactive medical alert hardware, products that generated one-time revenue and were predominantly targeting the business-to-government (B2G) market, which LogicMark says it has not only penetrated but is strong in despite fierce barriers to entry. Since 2021, the company’s transformation has been in full gear, coinciding with the appointment of CEO Chia-Lin Simmons, who remains at the helm. LogicMark reports that it has since expanded from a one-time revenue model to one that includes recurring subscription revenue with a very good lifetime value. Its latest products exist in white-hot areas such as AI, software-as-a-service and mobile applications, while it has also broadened its reach to include business-to-business (B2B) and business-to-consumer (B2C) channels. The LogicMark ecosystem integrates proprietary AI and machine learning technologies, facilitating ongoing connectivity and scalability. How LogicMark’s Products Can Be A Lifeline In Distress LogicMark has no shortage of products and solutions from which senior citizens and others can choose that could serve as a lifeline in times of distress. While LogicMark offers numerous products and services, here are a couple that are uniquely fit for seniors: Freedom Alert Mini: The newest in its line of mobile medical alert devices, Freedom Alert Mini brings revolutionary technology to medical alert devices. 24/7 monitoring means this device will always reach help and ensure wearers receive critical assistance. Fall detection will alert emergency services even when the fallen can't speak. GPS location services allow caregivers to monitor device location at all times. Caregivers can set geofencing boundaries to receive alerts when those under their care may wander. The Care Village app provides ultimate reassurance as a hub for emergency alerts, device status and geofencing boundary management. Guardian Alert 911 Plus: Guardian Alert 911 Plus is a 4G LTE technology that gives wearers peace of mind to travel anywhere within range of a cellular network. An industry-leading battery life means Guardian Alert 911 Plus only needs to be charged every 3-6 months, based on battery monitoring settings. LogicMark brought two-way voice communication to medical alert device technology. Guardian Alert 911 Plus can be worn on a lanyard, in a belt clip or on a wrist strap. This device is a one-time purchase, requiring no monthly monitoring fees. Aster: For aging adults who have a cell phone and are not ready for a traditional medical alert device, LogicMark offers Aster, a personal safety app that connects directly to a monitoring service to ensure the user's safety. In an emergency, a swipe will immediately connect them to monitoring professionals who will stay on the line and dispatch emergency services to help. A press and hold will allow all aging adults to arm the app when they don't feel safe and call help when they release. The follow me feature allows users to schedule events or appointments that they would like a check-in after, to make sure they have left safely. The Bluetooth button can be clipped to a keychain or purse to call emergency services immediately when help is needed. Freedom Alert Plus: Freedom Alert Plus is an in-home, Wi-Fi-powered medical alert device. LogicMark reports that it is the first of its kind with a touch screen and fall detection, making the device the ultimate safety companion for around the home and yard. 24/7 monitoring means emergency professionals are always available to dispatch help when wearers need it. Care Village provides caregivers with peace of mind, knowing they will always receive alerts when their loved one needs assistance. They can monitor device battery life and Wi-Fi connection to make sure Freedom Alert Plus will connect to emergency services. The issues around personal safety and independence are not going to disappear by themselves. Investors who are interested in participating in this digitization of the personal safety market can check out LogicMark’s investment deck here. Featured photo by Oppo Find X5 Pro on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 24, 2024 08:45 AM Eastern Daylight Time

Image

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

New Immuno-Oncology Research Team in Partnership with Ono Pharmaceutical Starts at BioMed X Institute

BioMed X Institute

BioMed X, a German biomedical research institute, announced the start of a new research team at the BioMed X Institute in Heidelberg, Germany, the institute’s first joint research project with the Japanese company Ono Pharmaceutical Co., Ltd. The scope of this project is to investigate the antitumor effects of neutrophils to develop novel next-generation immunotherapies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems paradoxical according to the current data. “We know far more about T cells in the context of immunotherapy than we know about neutrophils, but distinct immune cell types, including neutrophils, seem to have a potential to exert antitumor effect, while their biology remains unclear. By understanding neutrophil biology in depth, we aim to develop a wider range of effective therapies for cancer patients” explains Dr. Stefanie Bärthel, the group leader of the new research team in partnership with Ono Pharmaceutical. Dr. Bärthel, a Klaus Tschira Boost Fund Fellow in 2023, was a senior scientist at the German Cancer Research Center (DKFZ) in Heidelberg and the Center for Translational Cancer Research (TranslaTUM) in Munich before joining BioMed X as a group leader. “We are delighted to form a team of outstanding scientists with unique ideas on neutrophil-based immunotherapy through our innovative partnership with BioMed X. We believe that the research undertaken by this team will pave the way for the development of groundbreaking treatments,” said Dr. Seishi Katsumata, Corporate Officer/Executive Director, Discovery & Research at Ono Pharmaceutical. “This is our first research team in collaboration with a Japanese company. We are honored by the trust placed in us by Ono Pharmaceutical and look forward to extending our network of collaborators in Japan,” added Dr. Christian Tidona, Founder and Managing Director of the BioMed X Institute. The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany, and two research groups overseas, one at the BioMed X Institute in New Haven, CT, and one at XSeed Labs, a new type of innovation accelerator on the campus of the pharmaceutical company Boehringer Ingelheim in Ridgefield, CT. To read more about research and innovation at BioMed X, visit their website: www.bio.mx. About BioMed X BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun. About Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. ONO focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company’s website at www.ono-pharma.com/en. Contact Details BioMed X Institute Flavia-Bianca Cristian +49 6221 42611706 fbc@bio.mx Company Website https://www.bio.mx/

September 17, 2024 06:00 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 174